All In Biotech

Drug Trial Radar · NCT05534165

Tecovirimat in Non-hospitalized Patients With Monkeypox

Placebo-controlled Randomized Trial of Tecovirimat in Non-hospitalized Patients With Monkeypox: Canadian Feasibility Study (PLATINUM-CAN)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 14, 2023

Primary completion

Mar 13, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Marina KleinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre; University Health Network, Toronto; Unity Health Toronto; University of British Columbia; CIHR Canadian HIV Trials Network
First posted
Sep 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with presumptive or PCR confirmed monkeypox infection. The study will provide evidence on the efficacy and safety of Tecovirimat for laboratory-confirmed monkeypox in outpatients with monkeypox infection and determine the feasibility of conducting interventional monkeypox trials in Canada.

Conditions

  • Monkeypox

Interventions

  • TecovirimatDrug

    600 mg po BID

  • PlaceboDrug

    identical placebo 600 mg po BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to active lesion resolutionTime frame: Up to 28 days after randomization
  2. Feasibility and acceptability of conducting a pragmatic phase 3 interventional trial for outpatients with Monkeypox in CanadaTime frame: 4 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • St. Paul's Hospital, BC Centre for Excellence in HIV/AIDS

    Vancouver, British Columbia, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.